<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ppharm</journal-id><journal-title-group><journal-title xml:lang="ru">Педиатрическая фармакология</journal-title><trans-title-group xml:lang="en"><trans-title>Pediatric pharmacology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1727-5776</issn><issn pub-type="epub">2500-3089</issn><publisher><publisher-name>Издательство «ПедиатрЪ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15690/pf.v11i2.951</article-id><article-id custom-type="elpub" pub-id-type="custom">ppharm-114</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>ДЕЙСТВИЕ БИКЛОТИМОЛА НА МИКРОБИОТУ СЛИЗИСТОЙ ОБОЛОЧКИ ПОЛОСТИ РТА У ДЕТЕЙ</article-title><trans-title-group xml:lang="en"><trans-title>EFFECT OF BICLOTYMOL ON MOUTH CAVITY MUCOSAL MICROBIOTA IN CHILDREN</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Катосова</surname><given-names>Л. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Katosova</surname><given-names>L. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор биологических наук, профессор, главный научный сотрудник лаборатории микробиологии НИИ педиатрии ФГБУ «Научный центр здоровья детей»</p></bio><bio xml:lang="en"><p>PhD, Professor, senior research scientist at the microbiology laboratory of the research institute of pediatrics of the Scientific Center of Children’s Health (Federal State Budgetary Institution)</p></bio><email xlink:type="simple">Katosova@nczd.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лазарева</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lazareva</surname><given-names>A. V.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пономаренко</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ponomarenko</surname><given-names>O. A.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научный центр здоровья детей, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific Center of Children’s Health, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научный центр здоровья детей, Москва, Российская Федерация</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific Center of Children’s Health, Moscow, Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>04</day><month>04</month><year>2014</year></pub-date><volume>11</volume><issue>2</issue><issue-title>Педиатрическая фармакология</issue-title><fpage>13</fpage><lpage>18</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Катосова Л.К., Лазарева А.В., Пономаренко О.А., 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="ru">Катосова Л.К., Лазарева А.В., Пономаренко О.А.</copyright-holder><copyright-holder xml:lang="en">Katosova L.K., Lazareva A.V., Ponomarenko O.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pedpharma.ru/jour/article/view/114">https://www.pedpharma.ru/jour/article/view/114</self-uri><abstract/><trans-abstract xml:lang="en"><p>Introduction. Biclotymol [bis(chloro-4-thymol)methyl] is a biphenol derivative used for local treatment of pharyngeal inflammatory diseases. It is an antiseptic drug with bacteriostatic and bactericidal effects. Objective: evaluation of the drug’s antibacterial activity towards opportunistic and normal oropharyngeal microflora and identification of its minimum bactericidal concentration for the main bacterial pathogens of the upper respiratory tract. Results: we revealed that antibacterial effect of biclotymol on mouth cavity microbiota manifests itself with elimination of such species and genera of opportunistic microflora as Staphylococcus aureus, Streptococcus pyogenes, Haemophilus spp. and anginosus streptococci. We also revealed antibacterial activity of biclotymol against normal microbiota representatives, which included viridans streptococci. Out of this group of streptococci, only 1/3 of the initial amount of Streptococcus salivarius remained in place. Alongside identification of the minimum inhibitory concentration (MIC) of biclotymol against opportunistic microflora we revealed the most sensitive bacteria requiring the lesser drug concentration for the antibacterial effect to take place – Streptococcus pneumoniae and Haemophilus influenzae; intermediate – Moraxella catarrhalis, S. pyogenes and S. aureus; and resistant – non-pathogenic Neisseria species. Among the strains that survived biclotymol exposure, MIC was the highest in Neisseria spp. – 20 mg/ml after a 30‑minute-long exposure. Conclusions: results of a study of antibacterial effect of a topical antiseptic containing biclotymol demonstrated that the drug’s bactericidal activity is primarily aimed at gram-positive cocci represented both by opportunistic and non-pathogenic microbes. Non-pathogenic Neisseria species abundantly inhabiting mouth cavity mucosae and gram-negative rod-like microbes, which are uncharacteristic of the biotope under study, appeared to be resistant to bactericidal effect of biclotymol. Preservation of these microbes may somewhat prevent oropharyngeal colonization by undesirable pathogenic species.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>биклотимол</kwd><kwd>антисептики</kwd><kwd>антибактериальная активность</kwd><kwd>Streptococcus pneumoniae</kwd><kwd>Haemophilus influenzae</kwd><kwd>Moraxella catarrhalis</kwd><kwd>Streptococcus pyogenes</kwd><kwd>Staphylococcus aureus</kwd><kwd>Neisseria spp.</kwd><kwd>лечение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>biclotymol</kwd><kwd>antiseptics</kwd><kwd>antibacterial activity</kwd><kwd>Streptococcus pneumonia</kwd><kwd>Haemophilus influenza</kwd><kwd>Moraxella catarrhalis</kwd><kwd>Streptococcus pyogenes</kwd><kwd>Staphylococcus aureus</kwd><kwd>Neisseria spp.</kwd><kwd>treatment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Катосова Л. К., Лазарева А. В., Пономаренко О. П., Крыжановская О. А., Маянский Н. А. Антибактериальная эффективность биклотимола в отношении условно-патогенной микрофлоры верхних дыхательных путей. Вопросы диагностики в педиатрии. 2013; 5 (4): 28–32.</mixed-citation><mixed-citation xml:lang="en">Katosova L.K., Lazareva A.V., Ponomarenko O.P., Kryzhanovskaya O.A., Mayanskii N.A. Voprosy diagnostiki v pediatrii = Pediatric diagnostics. 2013; 5(4): 28–32.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Бочков И. А. Симбиотическая микрофлора глотки и ее роль в резистентности организма человека к инфекции. Журнал микробиологии, эпидемиологии и иммунологии. 1979; 3: 9–14.</mixed-citation><mixed-citation xml:lang="en">Bochkov I.A. Zhurnal mikrobiologii, epidemiologii i immunologii = Journal of microbiology, epidemiology and immunology. 1979; 3: 9–14.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Блинкова Л. П., Дорофеева Е. С., Батуро А. П., Романенко Э. Е., Катосова Л. К., Поликарпова С. В., Пивкина Н. В. Выявление бактериоциногенности среди возбудителей оппортунистических инфекций. Вестник Российской АМН. 2008; 4: 14–18.</mixed-citation><mixed-citation xml:lang="en">Blinkova L.P., Dorofeeva E.S., Baturo A.P., Romanenko E.E., Katosova L.K., Polikarpova S.V., Pivkina N.V. Vestnik Rossiiskoi AMN = Annals of RAMS. 2008; 4: 14–18.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
